Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Patients with colorectal cancer with mutated PIK3CA, identified from two large observational cohorts, had increased cancer-specific and overall survival if they used aspirin regularly after diagnosis compared to non-users. No effect of aspirin was seen in patients with wild-type PIK3CA. Mutated PIK3CA might be a useful biomarker to select patients who would benefit from adjuvant aspirin therapy.

Original publication

DOI

10.1038/nrclinonc.2012.216

Type

Journal article

Journal

Nat Rev Clin Oncol

Publication Date

01/2013

Volume

10

Pages

8 - 10

Keywords

Anti-Inflammatory Agents, Non-Steroidal, Aspirin, Biomarkers, Tumor, Colorectal Neoplasms, Humans, Mutation, Phosphatidylinositol 3-Kinases, Prognosis, Survival Rate